Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.
|Country:||Turks & Caicos Islands|
|Published (Last):||16 March 2004|
|PDF File Size:||17.34 Mb|
|ePub File Size:||17.83 Mb|
|Price:||Free* [*Free Regsitration Required]|
Click here to change registered Email ID.
ESOS provides that the grant price of options will be the latest available closing price on the stock exchange on which the shares of the Company are listed, prior to the date of the meeting of the Committee in which the options are granted. Company overview Ranbaxy Laboratories Limited ”the Company” together with its subsidiaries and associates, operates as an integrated international pharmaceutical organisation with businesses encompassing the entire value chain in the marketing, production and distribution of pharmaceutical products.
Segment information In accordance with AS 17, Segment Reporting, segment information has been given in the consolidated fnancial statements of the Company, and therefore, no separate disclosure on segment information is given in these fnancial statements. Related party disclosures A] Names of related parties Related parties where control exists with whom no transactions have taken place during the current period or previous year: Since the matter involves signifcant judgement and in view of the inherent uncertainty of the present situation, the actual amounts may differ eventually.
Due to the nature of these disputes and also in view of signifcant uncertainty of outcome, the Company believes that the amount of exposure cannot be currently determinable. Hence, the Company has become a potentially sick company in terms of the provisions of Sick Industrial Companies Special Provisions Act, and requisite compliances under this Act would be made by the Company.
The Company has challenged the order before the Hon”ble Income Tax Appellate Tribunal ITAT and pending disposal of the matter, the management considers the amount of tax liability as unascertainable. Foreign funds hint at hiking India allocation 25 Mar 10 Key markets of US, Europe not so promising 27 Oct 09 Ranbaxy UK Limited, U. A, Italy Ranbaxy Malaysia Sdn.
Your Account is not yet activated Click here to ov activation mail once again. In calculating these provisions, the management has used the best information and estimates, presently available.
Thank you for your kind understanding.
Annual Reports | Sun Pharmaceutical Industries Ltd.
Commitments i Estimated amount of contracts remaining to be executed on capital account and not Dion Global Solutions Limited. Description cannot exceed characters. Pursuant to the transaction, the Company has recorded a gain of Rs.
The sales consideration of Rs.
Daiichi Sankyo Propharma Co. The Company is in dialogue with these regulatory agencies and is addressing their concerns. Free reports will not be deducted from your subscription.
The following are the outstanding derivative contracts entered into by the Company: You will be able to download it at any time during the subscription period.
The effective portion of such cash fow hedges was recorded as part of reserves and surplus within hedging reserve and re-classifed in the Statement of Proft and Loss in the period corresponding to the occurrence of the highly probable forecasted transactions.
Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.
ESOP – provides that the grant price will be the face value of the equity share.
Ranbaxy Laboratories Limited (BSE Code: ) annual reports starting from year
Consequently, stock write off and other costs of Rs. Ranbaxy Laboratories is not traded in the last 30 days.
The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India.
ESOS I and II provide that the grant price of options is to be determined at the average of the daily closing price of the Company”s equity shares on the NSE during a period of 26 weeks preceding the date of the grant.
Quick Links for ranbaxylaboratories. The amount recognised in the Statement of Proft and Loss represents consequential cost sales return, inventory write off and customer claim recognised by the Company. Pending disposal of the matter, the management considers the impact as unascertainable.
The Company received the fnal assessment order from the AO in November whereby demand of Rs However, considering the above matters relating to the Toansa manufacturing facility, provisions primarily relating to inventories, trade commitments, sales return etc. Contingent liabilities and commitments to the extent not provided for As at As at 31 March 31 December Contingent liabilities i Guarantees a Letter of comfort on behalf of subsidiaries, to the extent of limits 6, As per the Scheme, the share exchange ratio has been proposed as 0.
This scheme limits the maximum grant of options to an employee or a director at 30, in any given year. Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs. Please do try to use an alternate pdf reader in case the file is unopenable with adobe.
These derivatives are not used for trading or speculation purposes.
The Company has not accepted the same and has fled its objections before the DRP. RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage rsport for human health careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents.